Advantage Investment Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Advantage Investment Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-560	Closed	-$3K	–	1004
2017 Q3	$3K	Hold	560	–	–	﹤0.01%	884
2017 Q2	$3K	Hold	560	–	–	﹤0.01%	901
2017 Q1	$5K	Hold	560	–	–	﹤0.01%	800
2016 Q4	$4K	Hold	560	–	–	﹤0.01%	768
2016 Q3	$2K	Hold	560	–	–	﹤0.01%	817
2016 Q2	$2K	Hold	560	–	–	﹤0.01%	774
2016 Q1	$2K	Hold	560	–	–	﹤0.01%	761
2015 Q4	$6K	Hold	560	–	–	﹤0.01%	653
2015 Q3	$6K	Buy	+560	New	+$7.47K	﹤0.01%	622

Other funds holding BCRX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Advantage Investment Management's BCRX Position: Q4 2017 in Review

Advantage Investment Management sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2017, closing a stake of 560 shares — an estimated $3K sold.

Advantage Investment Management first reported a position in BCRX in Q3 2015 and held it in 9 quarters. The position peaked at $6K in Q4 2015. 116 funds tracked by Wall St. Rank hold BCRX as of Q4 2017.

Advantage Investment Management reported no remaining BioCryst Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
Advantage Investment Management sold 560 BioCryst Pharmaceuticals shares in Q4 2017, an estimated $3K.
Advantage Investment Management first reported a position in BioCryst Pharmaceuticals in Q3 2015 and held it in 9 quarters.
Advantage Investment Management's BioCryst Pharmaceuticals position peaked at $6K in Q4 2015.
116 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2017.

Based on Advantage Investment Management's 13F filing for Q4 2017, filed 12 Feb 2018.